Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 19/20 | 0.66 |
| ▸ | ACHE | P22303 | 15/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703732 | 0.92 | HTR4 (0.58) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| SCHEMBL7688094 | 0.87 | HTR4 (0.61) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| SCHEMBL6699852 | 0.81 | ACHE (0.47) | HTR4ACHESIGMAR1ALDH1A1TSHR | |
| SCHEMBL6702783 | 0.81 | HTR4 (0.47) | HTR4ACHESIGMAR1ALDH1A1TSHR | |
| SCHEMBL30139057 | 0.80 | ACHE (1.00) | HTR4ACHESIGMAR1 | |
| SCHEMBL17709631 | 0.80 | ACHE (1.00) | HTR4ACHESIGMAR1 | |
| SCHEMBL17709636 | 0.80 | ACHE (1.00) | HTR4ACHESIGMAR1 | |
| SCHEMBL6983685 | 0.80 | ACHE (0.47) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| SCHEMBL6698989 | 0.79 | ACHE (0.46) | HTR4ACHESIGMAR1MEN1ALDH1A1 | |
| SCHEMBL6702788 | 0.79 | ACHE (0.62) | HTR4ACHESIGMAR1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114408-B1 | SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100113492-A1 | Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113492-A1 | Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators | CCKAR, CCKBR, GLP1R | HTR4 197/4885ACHE 4028/4885SIGMAR1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.